Teewinot Life Sciences Secures First U.S. Patent Covering a Commercial Process for Biosynthetic Production of authentic THCA, CBDA and CBCA Cannabinoids
Furthers Mission to Address Unmet Medical Needs Across the Globe
TAMPA, Florida, June 7, 2016 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of synthetic biology to create pharmaceutical grade cannabinoids, announced today that it was granted the first U.S. Patent covering a commercial process for biosynthetic production of the cannabinoids THCA, CBDA and CBCA. U.S. Patent No. 9,359,625 ("the '625 patent") is scheduled to grant today and is owned by Full Spectrum Laboratories, Ltd., Teewinot's wholly owned Irish subsidiary. The '625 patent claims a biosynthetic process for manufacturing the cannabinoids THCA, CBDA and CBCA using THCA synthase and CBDA synthase. Advantages to this method include the ability to produce quickly biocatalyzed authentic cannabinoids that are purer in form, more cost efficient and have less environmental impact than what is currently available in the marketplace.
"Teewinot has a powerful platform of technologies involving synthetic biology, bioinformatics, biocatalysis and chemical synthesis for the efficient production of large quantities of cannabinoids including THCA, CBCA, CBDA, as well as cannabinoid pro-drugs and analogs," said Richard Peet, Teewinot's executive vice president. "Our patent portfolio is rapidly expanding in the U.S. and key countries around the world."
Teewinot is scaling up its proprietary processes in collaboration with Albany Molecular Research, Inc., a leading U.S. contract research organization (CRO). With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is poised to become a leading cannabinoid manufacturer worldwide.
"Teewinot is a biopharmaceutical company focused on the production of cannabinoids and the discovery, development and commercialization of cannabinoid-based therapeutics for significant unmet medical needs across the globe," said Jeff Korentur, Teewinot's CEO. "Our use of synthetic biology represents a significant advancement from current plant extraction and chemical synthesis methods. We are seeking partners interested in using the cannabinoids, cannabinoid pro-drugs and cannabinoid analogs we manufacture in research and clinical trials to fill critical gaps in current, and future pharmaceutical offerings."
About Teewinot Life Sciences Corporation
Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid based therapies. With headquarters in Tampa, Florida, Teewinot manufactures and licenses technology to make cost effective, pharmaceutically pure authentic cannabinoids as an industry leader in support of advancing medical research and product development. Teewinot's global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines. For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).
For More Information:
Teewinot Life Sciences Corporation
Jeffrey M. Korentur
President & CEO
jeff@tlscorp.com
813.501.5021
Share this article